Comparative Pharmacology
Head-to-head clinical analysis: FORADIL CERTIHALER versus TORNALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORADIL CERTIHALER versus TORNALATE.
FORADIL CERTIHALER vs TORNALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
One inhalation (12 mcg) twice daily via oral inhalation.
2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.
None Documented
None Documented
The terminal elimination half-life of formoterol (active component) ranges from 5 to 10 hours following inhalation. This supports twice-daily dosing, though clinical effect may persist longer due to prolonged receptor binding.
Terminal elimination half-life is approximately 9-12 hours in healthy adults. May be prolonged in elderly or those with hepatic impairment, necessitating dose adjustment.
After oral inhalation, the majority of a dose is excreted in feces (up to 70%) as unchanged drug and metabolites via biliary elimination. Renal excretion accounts for approximately 13-25% of the dose, primarily as metabolites. Unabsorbed drug accounts for the remainder.
Primarily renal excretion of unchanged drug and metabolites; <10% fecal. Approximately 60-70% of a dose is recovered in urine as unchanged drug and glucuronide conjugates within 24 hours.
Category C
Category C
Bronchodilator
Bronchodilator